Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi‐Long Wu, Tony Mok, Kazuhiko Nakagawa et al.|The Lancet Oncology|2017Cited by 1.2k
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227Julie R. Brahmer, Suresh S. Ramalingam, Jong-Seok Lee et al.|Journal of Clinical Oncology|2022Cited by 375